44 results about "Increased platelets" patented technology

A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): wherein A is a C?2-14#191 aryl group, B is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, D is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, and E is a C?2-14#191 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the activator or a solvate thereof, as an active ingredient.

The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention relates to compositions and methods for providing improved platelet levels, useful in the treatment and prevention of thrombocytopenia, for controlling bleeding and for inducing or modulating haemostasis.

2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided.

The invention relates to the adhesion of platelet GpIbα to strand β3 of domain A1 of von Willebrand factor (vWF), the strand β3 comprising amino acid residues at amino acid position 560-566 and/or a functional part or equivalent thereof, the platelet GpIbα, the GpIbα region comprising an amino acid sequence corresponding to a beta-switch loop of platelet GpIbα, comprising amino acid residues at amino acid position 227-242 and/or a functional part or equivalent thereof. The invention provides a method of interfering with adhesion of blood platelets to vWF that includes modulating adhesion. The invention further provides proteinaceous compounds, antibodies, medicaments and pharmaceutical compositions to that end. The invention also provides means and methods to increase platelet adhesion by topical application of a compound increasing platelet adhesion.

The invention belongs to the field of biomedical materials, and relates to a preparation method of a controllably-degraded RGD phage/fibroin composite quick hemostatic material. The invention provides the controllably-degraded RGD phage/fibroin hemostatic material prepared by using a fibroin-prepared bioabsorbable natural biological material as a supporting part and combining the supporting part with RGD phage, and the RGD phage/fibroin hemostatic material has a significant blood coagulation promoting effect. The RGD phage/fibroin hemostatic material is mainly applied to hemostasis of skin wounds and organs, and is an ideal hemostatic material. The RGD phage/fibroin hemostatic material has the following outstanding characteristics: (1) treated fibroin can attract negatively charged platelets and red blood cells in blood so as to increase platelet adhesion and promote thrombosis; (2) after a certain period of time, RGD phage/fibroin porous hemostatic material can be degraded and reabsorbed by a body, so that a scab is not formed at a wound position; and (3) the RGD phage/fibroin composite quick hemostatic material does not simply depend on the hemostatic ability, and through compounding of the RGD phage, the hemostatic speed of the hemostatic material is increased and the hemostatic effect of the hemostatic material is improved.

The invention discloses a method for increasing the production of hematopoietic stem cells. The method includes administering a TPO mimetic compound to a subject. The invention also discloses a pharmaceutical composition comprising a TPO mimetic compound and a pharmaceutically acceptable carrier.

The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets of platelet precursors (e.g., megakaryocytes) in a mammal.

Disclosed are methods for treating bleeding disorders, such as hemophilia, in subjects in need thereof by administering an antibody that specifically binds CD73. The methods reduce production of adenosine, increase platelet activation and/or enhance the level of coagulation on the platelet surface to reduce and/or stop bleeding. In some embodiments, the methods can further include co-administering Factor VIII to treat the bleeding disorder.

Disclosed in certain embodiments is an oral pharmaceutical dosage form comprising a pharmaceutically acceptable excipient and an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperadine-4-carboxylic acid (Formula I) or a pharmaceutically acceptable salt thereof, to increase platelet levels in humans.

Platelets are induced to proliferate, form extensions and produce daughter cells by various methods, including culturing platelets under thrombocytopenic conditions. Expansion of platelet cell numbers increases the storage life of platelets. Modulation of RT activity can be used to produce new daughter platelets. Therefore, the invention provides a new therapeutic use for RT inhibitors that can now be used for treatment of thrombocytopenia and related disorders. Likewise, application of soluble protein factor that may be secreted and/or released by platelets cultured under thrombocytopenic conditions may also be used as a therapeutic agent to increase platelet numbers.

Provided are methods for increasing platelet response in a subject at risk for bleeding due at least in part to a low platelet count by administering to a subject with a low platelet count an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridine-2-yl)piperidine-4-carboxylic acid.

The invention discloses styptic preparation and a preparation method thereof. The styptic preparation is bittersweet ethyl acetate extract, has the effect of increasing platelet quantity and can be used for shortening blood coagulation time and bleeding time, so that the styptic preparation can be developed into a styptic oral drug and can be used for treating bleeding caused by hypermenorrhea, metrorrhagia and metrostaxis of women and birth control measures.